Amgen: Biotech Giant's Path to Growth and Recovery
Amgen has navigated headwinds to chart a path toward renewed growth. This analysis breaks down the catalysts, risks, ...
Compare 6-month and 12-month emergency funds to determine the best target for your finances, weighing liquidity, security, and timelines.
24,819 articlesAmgen has navigated headwinds to chart a path toward renewed growth. This analysis breaks down the catalysts, risks, ...
Balancing college funding for your kids with your retirement goals can feel impossible. This guide shows a practical ...
When a mining stock pops today, investors sit up. Discover the drivers behind SSR Mining's rally, what it means for r...
Can a defense-focused ETF outperform a jet-fueled recovery play in 2026? This deep dive examines PPA and JETS, weighi...
KBR faced a two-sided story: a massive backlog that hints at strong future demand, and a prominent investor trimming ...
A practical guide to interpreting Champions Oncology earnings. We break down the numbers, trends, and what to watch n...
A Nvidia-backed push into AI infrastructure sent Marvell Technology higher, highlighting how AI-focused hardware may ...
As AI hype cools and traditional earnings prove steadier, the market posture may be sending subtle signals. This arti...
The market has rallied, but high valuations ring warning bells. This guide explains what the stock market sounds alar...
A 5% pullback in the Nasdaq in 2026 echoes big past moves and offers clues about which stocks tend to fare best durin...
When a fast-growing retailer loses momentum, the stock often gets pulled back. This article breaks down why five belo...
When homes linger on the market, buyers gain negotiating power and lenders adjust terms. This guide explains how stal...